Home
HelpTest Code 10INE Factor X Inhibitor Evaluation, Plasma
Ordering Guidance
This test is for factor X inhibitors only. If the presence or type of inhibitor is unknown, first order APROL / Prolonged Clot Time Profile, Plasma, except for patients with known hemophilia A or B. When screening studies are needed for patients with known hemophilia A or B, order 8INHE / Factor VIII Inhibitor Evaluation, Plasma; or 9 INHE / Factor IX Inhibitor Evaluation, Plasma; respectively.
Shipping Instructions
Send all vials in the same shipping container.
Necessary Information
Specimen Required
Specimen Type: Platelet-poor plasma
Patient Preparation:
1. Patient must not be receiving Coumadin (warfarin) or heparin therapy
2. Fasting preferred
Collection Container/Tube: Light-blue top (3.2% sodium citrate)
Submission Container/Tube: Plastic vials
Specimen Volume: 3 mL in 3 plastic vials, each containing 1 mL
Collection Instructions:
1. Specimen must be collected prior to factor replacement therapy.
2. For complete instructions, see Coagulation Guidelines for Specimen Handling and Processing.
3. Centrifuge, transfer all plasma into a plastic vial, and centrifuge plasma again.
4. Aliquot plasma (1-2 mL per aliquot) into 3 separate plastic vials, leaving 0.25 mL in the bottom of centrifuged vial.
5. Freeze plasma immediately (no longer than 4 hours after collection) at -20° C or, ideally, -40° C or below.
Additional Information:
1. Double-centrifuged specimen is critical for accurate results as platelet contamination may cause spurious results.
2. Each coagulation assay requested should have its own vial.
Useful For
Detection and quantitation of inhibitor to coagulation factor X
This test is not useful for the detection of a lupus-like circulating anticoagulant inhibitor, a nonspecific circulating anticoagulant, or other inhibitors that are not specific for coagulation factors.
Profile Information
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| 10INT | FX Inhib Profile Tech Interp | No | Yes |
| F_10 | Coag Factor X Assay, P | Yes | Yes |
Reflex Tests
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| 10AIH | FX Inhib Profile Prof Interp | No | No |
| 10_IS | Factor X Inhib Scrn | No | No |
| GBETH | General Factor Bethesda Units, P | No | No |
Testing Algorithm
Testing begins with coagulation factor X activity assay with dilutions to evaluate assay inhibition; if the factor X activity assay is normal or increased, then a technical interpretation will be provided.
If the factor X activity assay is decreased, then an inhibitor screen will be performed at an additional charge to look for specific factor X inhibition and a professional interpretation will be provided. If specific inhibition is apparent, the titer of the inhibitor will be determined.
Special Instructions
Method Name
F_10, 10_IS, GBETH: Optical Clot-Based
10INT: Technical Interpretation
10AIH: Medical Interpretation
Reporting Name
Factor X Inhib Profile, PSpecimen Type
Plasma Na CitSpecimen Minimum Volume
2 Plastic vials, each containing 1 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Plasma Na Cit | Frozen | 14 days |
Reject Due To
| Gross hemolysis | Reject |
| Gross lipemia | Reject |
| Gross icterus | Reject |
Clinical Information
Coagulation factor inhibitors arise in patients who are congenitally deficient in a specific factor in response to factor replacement therapy, or they can either occur spontaneously without known cause or in response to a variety of medical conditions, including the postpartum state, immunologic disorders, certain antibiotic therapies, some malignancies, and in the older population.
Inhibitors of factor VIII coagulant activity are the most commonly occurring of the specific factor inhibitors.
Reference Values
FACTOR X ACTIVITY ASSAY
Adults: 70-150%
Normal, full-term newborn infants or healthy premature infants may have decreased levels (≥15-20%) that may not reach adult levels for 180 days or more postnatal.*
*See Pediatric Hemostasis References section in Coagulation Guidelines for Specimen Handling and Processing.
FACTOR X INHIBITOR SCREEN:
Negative
GENERAL FACTOR BETHESDA UNITS:
≤0.5 Bethesda Units
Interpretation
Normally, there is no inhibitor, ie, negative result.
If the screening assays indicate the presence of an inhibitor, it will be quantitated and reported in Bethesda (or equivalent) units.
Cautions
Occasionally, a potent lupus-like anticoagulant may cause false-positive testing for a specific factor inhibitor (eg, factor VIII or IX).
Method Description
Screening for inhibitors of specific coagulation factors is represented by the inhibitor assay for factor X. This assay consists of measuring the difference in factor X activity (prothrombin time based assay) before and after incubation of a mixture of normal plasma and patient's plasma for 1 hour at 37° C. For optimal sensitivity, the factor X value of the normal plasma is adjusted to approximately 20%, because the factor X assay is more sensitive in this area of the curve. In addition, an excess of patient's plasma will make the test more sensitive to small amounts of inhibitors.(Owen CA Jr, Bowie EJW, Thompson JH Jr. The Diagnosis of Bleeding Disorders. 2nd ed. Little, Brown, and Company; 1975:143-145; Cielsa B. Defects of plasma clotting factors. In: Hematology in Practice. 3rd ed. FA Davis; 2019:chap 17)
If the inhibitor screen is positive for an inhibitor of factor X, the inhibitor will be quantitated by the "Bethesda assay." In the Bethesda procedure, inhibitors are quantified by mixing equal volumes of serially diluted plasma with normal plasma. This mixture is incubated 2 hours at 37° C, and its factor X activity is measured and compared to a control run at the same time. The difference between the factor X activity of the patient's incubation mixture and that of the control is used to calculate titer. The residual factor X activity is converted to "Bethesda units": 50% residual factor X is equal to 1 Bethesda unit.(Kasper CK, Aldedort LM, Counts RB, et al. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh. 1975;34:869-872; Cielsa B. Defects of plasma clotting factors. In: Hematology in Practice. 3rd ed. FA Davis; 2019:chap 17)
Day(s) Performed
Monday through Friday
Report Available
1 to 3 daysSpecimen Retention Time
7 daysPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
85390
85260
85335 (if appropriate)
85335 (if appropriate)
85390 (if appropriate)
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| 10INE | Factor X Inhib Profile, P | 96457-7 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 10INT | FX Inhib Profile Tech Interp | 69049-5 |
| F_10 | Coag Factor X Assay, P | 3218-5 |
Forms
If not ordering electronically, complete, print, and send a Coagulation Test Request (T753) with the specimen.